| Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. Co.'s product portfolio and potential indications include: roluperidone (also known as MIN-101) for the treatment of negative symptoms in patients with schizophrenia; seltorexant (also known as MIN-202 or JNJ-42847922), in which it is co-developing with Janssen Pharmaceutica NV for the treatment of insomnia disorder and adjunctive treatment of Major Depressive Disorder; and MIN-301 for the treatment of Parkinson's disease. We show 30 historical shares outstanding datapoints in our coverage of NERV's shares outstanding history.|
Understanding the changing numbers of NERV shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like NERV versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching NERV by allowing them to research NERV shares outstanding history
as well as any other stock in our coverage universe.